The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial loss in body size and improve metabolic health,… Read More